01.06.2014 • News

GSK Invites Private Equity Bids for Older Drugs

UK pharmaceutical producer GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs, news agencies report, citing people familiar with the matter.

The move is said to be part of a reshaping of the drugmaker's portfolio, which also involves a $20 billion asset swap with Novartis that will see the Swiss company acquiring GSK's oncology activities while GSK takes Novartis' vaccines business.

GSK chief Andrew Witty said last month that Britain's biggest pharmaceuticals company could dispose of individual medicines or a broader portfolio of older established products.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read